Our current pipeline

VTA-300: is an immunotherapy currently under development that combines proprietary chimeric antigen receptor (CAR) technology and gene editing to target an undisclosed indication.

VTA-100: is currently undergoing investigational new drug (IND)-enabling studies for the treatment of limb-girdle muscular dystrophy (LGMD) 2A/R1. It is designed to be an autologous treatment that combines gene correction and induced pluripotent stem cell (iPSC) technology to help repair and replace muscle cells. It is envisioned that transplanted Vita Therapeutics’ muscle stem cells (satellite cells) will not only replace and repair damaged muscle tissue but also, upon homing to the satellite cell niche in a quiescent state, support long lasting homeostasis and repair of future muscle damage.